At the time, Barron said that combinations of a PD-1 with TIGIT, CD96 and PVRIG inhibitors – the latter three all acting around the CD226 pathway – could become transformative medicines for ...
The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback